ArticleImmunity, inflammation and disease2026
Characterization of NLRP3 Inflammasome-Associated Hub Genes in the Progression of Diabetic Nephropathy.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of NLRP3 Inflammasome-Associated Hub Genes in the Progression of Diabetic Nephropathy.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is widely recognized as the primary cause of end-stage renal disease. However, the underlying mechanisms and pathogenesis of DN remain incompletely understood. Exploring novel biomarkers aiding in tracking the progression of DN has important clinical implications.
methodsHuman renal transcriptomic datasets (GSE142025 and GSE96804) from the Gene Expression Omnibus (GEO) were analyzed. Differentially expressed genes (DEGs) were identified using a staged analysis, which involved sequential comparisons between normal controls and early-stage DN, as well as between early DN (eDN) and advanced DN (aDN). Enrichment analysis of DEGs was performed using R software. WGCNA was utilized to construct gene co-expression networks and to identify the key genes. Then, Venn diagrams were generated using DEGs and key genes from both datasets to determine the final hub genes. ROC curves were then used to assess the diagnostic accuracy of hub genes for DN disease progression. Finally, we cross-validated the hub genes using the clinical kidney specimens.
resultsAfter analyzing the datasets, we identified 22 and 43 hub genes using the WGCNA and DEGs at the eDN and aDN stages. Further investigation of the literature on the hub genes led to the discovery of their association with the activity of NLRP3 inflammasome, including ZFP36, CLEC2D, and HCK, which were identified as NLRP3 inflammasome-associated hub genes (NIAHGs). We found that the AUC of all the NIAHGs can indicate their potential diagnostic value. Then, we validated the expression levels of NIAHGs in human renal tissues, which were consistent with those in both data sets. Importantly, immunoblot analysis indicated that NIAHGs expression was associated with NLRP3 inflammasome activation. Furthermore, NLRP3 inflammasome was significantly activated, leading to the release of large amounts of IL-1β and IL-18 in eDN, further initiating the inflammatory response in the diabetic kidney.
conclusionsOur findings identify critical hub genes associated with DN progression and NLRP3 inflammasome activity, providing a theoretical basis and candidate targets for subsequent research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.